A Landscape of Artificial Intelligence (AI) In Pharmaceutical R&D

Where you find opportunities to grow

* Can't find your brand, product, service? Join BPT Marketplace

Charlotte Tomic

Contributor

Charlotte Tomic is a public relations consultant who has worked with academic institutions, biotech companies, physicians, authors, nonprofits and companies of all sizes for more than 25 years. She is based in Miami Beach, FL after a long career in New York.

     

Biopharma news Biotech Startup Startups Biotech Research Cell Therapies Oncology

Disclaimer: All opinions, ideas, and thoughts expressed and posted by Contributors at BiopharmaTrend.com platform are their own personal points of view, and do not represent neither Contributor's employers, nor BiopharmaTrend.com.

Posts by this author

Cytovia Therapeutics and NYSCF Annouce Filing of Provisional Patent for iPSC-derived NK Cells to Produce Unlimited On-demand NK and CAR-NK Cells for the Treatment of Cancer

   101
Cytovia Therapeutics and NYSCF Annouce Filing of Provisional Patent for iPSC-derived NK Cells to Produce Unlimited On-demand NK and CAR-NK Cells for the Treatment of Cancer

(August 25, 2020)--New York, NY--Cytovia Therapeutics, an emerging biopharmaceutical company and the New York Stem Cell Foundation (NYSCF) Research Institute today announced the filing of a provisional patent application with the U.S. Patent & Trademark Office (USPTO) for the differentiation of Natural Killer (NK) cells from induced pluripotent stem cells (iPSCs). The NYSCF Research Institute is a pioneer and acknowledged leader in stem cell technology, having developed the NYSCF Global Stem Cell Array®, the premier automated robotic platform for reprogramming skin or blood into induced pluripotent stem cells (iPSCs) and differentiating them into disease-relevant cell types.